Wednesday November 13, 1:29 AM EST
Swiss biotech group Serono SA (SEOZ) has agreed to get the U.S. license for Amgen Inc's multiple sclerosis drug Novantrone, the partners said in a joint statement on Wednesday.
They gave no financial terms for the deal. Amgen got Novantrone when it acquired Immunex Corp in July.
Approved in October 2000 for treating multiple sclerosis, the drug had U.S. sales of $71 million in 2001. It has also been approved for some cancer indications since 1987.
The transaction still needs U.S. regulatory approval.
Serono, Europe's biggest biotech company, already has a successful MS franchise led by Rebif, its top-selling product. It said last month it aimed to develop the world's first pill for treating MS. Current medicines are given by injection.
U.S.-based Amgen is the world's biggest biotech firm.
© 2002 Reuters Limited